2.9 Evidence Behind the Case

Time To Read

4–5 minutes

Date Last Modified

The Just Enough Chemistry module reads the one thing Stina’s chart got right and no one acted on: inflammatory markers that ran high even between attacks, when she felt fine. This page pairs that logic with the literature — including why those numbers were not just real but dangerous — so the case stands as both a lived experience and a research-supported one.

This page belongs to a teaching case built around familial Mediterranean fever (FMF), an IL-1β-driven autoinflammatory disease. If you found it while searching a lab finding — for a patient, or for yourself — it is a valid, evidence-anchored starting point. 

Jump to it:

When Stina finally requested her own labs, she found years of high inflammatory markers, each stamped with some version of “likely stress” or “probably lab error.” She had been told she was fine while the numbers quietly said otherwise. The most validating sentence in her whole record came late: “persistently elevated acute-phase reactants.” Translated, the high markers that haunted her good weeks had been real, measurable, and ongoing the entire time. Stina is me.

In FMF, acute-phase reactants — C-reactive protein, ESR, and especially serum amyloid A (SAA) — are frequently elevated even in the symptom-free intervals between attacks, a state called subclinical or occult inflammation.1,2 This is not a curiosity: persistent SAA elevation is the substrate for AA amyloidosis, FMF’s most feared complication, and higher between-attack acute-phase levels predict amyloid risk.3,4 The numbers dismissed as “stress” were, in fact, the disease smoldering — and a warning about her kidneys and other organs years before anything failed.5

If you reached this page searching persistently elevated CRP or ESR of unknown cause, or subclinical inflammation, that is the page doing its job: in the right clinical story, those numbers are a diagnosis waiting to be made, not noise to be filtered out. The module also introduces the molecular cast the rest of the course follows — pyrin (the protein at the disease’s center), IL-1β (the signal it fails to restrain), and amyloid (a normal protein gone misfolded) — and lands Chart Clue #2: acute-phase proteins as hard evidence of hidden inflammation.

Parts 1, 7 · Chart Clue #2

Inflammatory markers elevated when the patient feels well are real evidence of ongoing disease — the defining “subclinical inflammation” of FMF, not lab error or stress.

Part 7

SAA is a sensitive acute-phase reactant that reveals inflammation during asymptomatic periods and helps gauge disease control in FMF.

Part 7

Between-attack elevation of CRP/ESR/SAA is a recognized feature of FMF and a target of treatment — the disease does not switch fully off between flares.

Part 7 · amyloid preview

Sustained high acute-phase reactants (especially SAA) drive AA amyloidosis, FMF’s lethal complication — so the ignored numbers were an early warning.

Stina is not a composite. Stina is me. The years of high markers stamped “stress” were mine, and so was the strange grief of reading, decades late, that they had been “persistently elevated acute-phase reactants” the whole time. Being told your abnormal labs are your imagination — while they quietly predict damage to your own kidneys — is a particular kind of harm, and it is why this module exists.

This page holds both truths at once. The lived experience — being disbelieved against the evidence of your own bloodwork — is the part a chart never records. The research support is what earns the case a place in a science course: the FMF-specific findings (subclinical SAA elevation, amyloidosis risk) are cited directly. If you are a clinician who arrived from a patient, treat this as a validated starting point that respects the patient’s experience and then hands you the literature. On behlaf of your patient, I ask you to consider measuring an SAA.

Grouped by the part of the argument they support.
Links verified August 2026.

List of terms